学术周报 · IF≥10

胃肠外科领域文献阅读汇编

2026年第44周 (2026-10-31) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
收录论文
5
临床研究
3
基础研究
2
IF≥20
0
IF 10-20
5
子领域
4
期刊种类
5
数据日期
2026-10-31

★本周 Top 10 高影响力文献

#论文期刊IF
1The Dual Reality of Psychological Outcomes and Mental Health Trajectories After Metabolic and Bariat...Current obesity reportsIF 17.0
2Comparison of Outcomes Between Men and Women Undergoing Ventral Hernia Repair.JAMA surgeryIF 15.6
3GPR183 senses 7α,25-OHC to drive Treg differentiation and tumor immune evasion via AXL-JAK2-STAT5 si...Science advancesIF 13.9
4The Future of Metabolic and Bariatric Surgery in the Glucagon-Like Peptide-1 Era: Has the Scalpel Be...Journal of obesity & metabolic syndromeIF 12.7
5IL-15 superagonists for reprogramming the immunosuppressive microenvironment in gastrointestinal ade...Cancer lettersIF 11.8

Ŧ期刊分布统计

期刊篇数IF
Science advances1IF 13.9
Journal of obesity & metabolic syndrome1IF 12.7
JAMA surgery1IF 15.6
Cancer letters1IF 11.8
Current obesity reports1IF 17.0

1减重/代谢手术 (2篇)

临床研究 (2篇)

Journal of obesity & metabolic syndrome IF 12.7 2026-10-30 PMID: 42843854
Obesity remains a growing global health crisis, affecting nearly one billion adults worldwide and substantially increasing the risk of cardiometabolic disease, malignancy, and premature mortality. Metabolic and bariatric surgery (MBS) has evolved into an effective and durable treatment for severe obesity, providing sustained weight loss and significant remission of obesity-related comorbidities (i.e., type 2 diabetes mellitus and cardiovascular disease). Despite dramatic improvements in safety, efficacy, and long-term outcomes over time, MBS remains markedly underutilized, reaching fewer than 1% of eligible patients. Persistent barriers include limited patient and provider awareness, misconceptions regarding surgical risk, and significant disparities in access to care. Concurrently, the rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has transformed the medical management of obesity, offering effective pharmacologic weight loss but raising questions regarding their impact on MBS utilization, durability, and cost-effectiveness. Emerging evidence demonstrates that while MBS produces greater and more durable weight loss than GLP-1 RAs alone, these therapies need not be competitive. Rather, GLP-1 RAs may serve as 'neoadjuvant' treatment to optimize surgical candidacy or as adjunctive treatment for inadequate weight loss or postoperative weight regain. This review synthesizes contemporary data on MBS procedures, outcomes, disparities in access, and evolving perceptions of obesity treatment in the GLP-1 RA era. We propose a chronic weight management model that integrates pharmacotherapy, surgery, and multidisciplinary care along a continuous treatment spectrum. Positioning MBS and GLP-1 RAs as complementary modalities within individualized care pathways may improve long-term outcomes, expand access, and better address the complex, chronic nature of obesity.
中文摘要:肥胖仍是一场不断加剧的全球健康危机,全球近十亿成人受累,心血管代谢疾病、恶性肿瘤与过早死亡的风险随之明显升高。代谢与减重手术(MBS)已发展为治疗重度肥胖有效且持久的手段,可带来持续的体重下降,并使肥胖相关合并症(如2型糖尿病与心血管疾病)获得显著缓解。尽管其安全性、疗效与长期结局不断大幅改善,MBS的应用仍明显不足,仅覆盖不足1%的符合条件患者。持续存在的障碍包括患者与医务人员认知有限、对外科风险的误解,以及就医可及性的显著差异。与此同时,胰高血糖素样肽-1受体激动剂(GLP-1 RA)的迅速普及改变了肥胖的药物治疗格局,可带来有效的药物性减重,但也引发其对MBS使用率、疗效持久性与成本效益影响的疑问。新出现的证据显示,MBS的减重幅度与持久性优于单用GLP-1 RA,但两类治疗并非必须相互竞争。相反,GLP-1 RA可作为「新辅助」治疗以优化手术适应证,或作为减重不足或术后体重反弹时的辅助治疗。本综述整合MBS术式、结局、可及性差异以及GLP-1 RA时代肥胖治疗观念演变的最新资料,并提出一种慢性体重管理模型,将药物治疗、手术与多学科照护沿连续的治疗谱系加以整合。在个体化诊疗路径中将MBS与GLP-1 RA定位为互补手段,可能改善长期结局、扩大可及性,并更好地应对肥胖复杂而慢性的本质。
Current obesity reports IF 17.0 2026-10-24 PMID: 42925358
To map, within a single integrated framework, the full spectrum of desirable ('feel-good') and less desirable ('feel-bad') psychological outcomes and mental health trajectories after metabolic and bariatric surgery (MBS), and to identify the knowledge gaps that emerge only when both sides are viewed together. Across 251 included studies, the desirable arm comprised four interconnected domains: improved mental health (depression, anxiety, mood, eating disorders); enhanced physical-health domains supporting psychological well-being; improved body image, self-esteem and relational functioning; and gains in occupational, educational and economic participation. The less desirable arm comprised three themes: a spectrum of adverse outcomes; the negotiation of self and existential tensions; and a 'lonely struggle' against insufficient support, encompassing the most serious outcomes of suicide, self-harm and alcohol-use disorder. Thirty-seven studies contributed to both arms, and benefits and burdens frequently coexisted within the same patient over time. Recent studies show that these gains are smaller and less durable than group averages suggest. Improvements in depressive and anxiety symptoms are largest in the first year and smaller thereafter or partly reversed; symptoms persist or worsen in a subset of patients; relationship, work, body-image, and weight-stigma outcomes run in both directions; and the benefits differ by sex, ethnicity, age group, and pre-surgical psychiatric history. The psychological aftermath of MBS is a dual reality rather than a uniformly positive or negative one. Reframing psychological success as the net balance between the two trajectories supports biopsychosocial, multidisciplinary, long-term care, and points to a research agenda built on within-cohort, dual-outcome longitudinal designs.
中文摘要:在一个整合框架内,梳理代谢与减重手术(MBS)后全部有利(感觉良好)与较不有利(感觉不佳)的心理结局和心理健康轨迹,并识别只有同时审视两方面才会显现的知识空白。共纳入251项研究,有利方面包含四个相互关联的领域:心理健康改善(抑郁、焦虑、情绪、进食障碍);支持心理福祉的躯体健康领域改善;身体意象、自尊和关系功能改善;职业、教育及经济参与方面的获益。较不有利方面包含三个主题:不良结局谱系;自我协商与存在性紧张;在支持不足下的「孤独挣扎」,涵盖自杀、自伤和酒精使用障碍等最严重结局。37项研究同时涉及两方面,获益与负担常在同一患者随时间推移中并存。近期研究显示,这些获益比组平均水平所提示的更小且更不持久。抑郁和焦虑症状的改善在术后第一年最大,此后较小或部分逆转;部分患者症状持续或加重;关系、工作、身体意象和体重污名结局呈双向变化;获益因性别、族裔、年龄组和术前精神病史而异。MBS的心理后效应是一种双重现实,而非一致积极或一致消极。将心理成功重新界定为两条轨迹之间的净平衡,支持生物心理社会、多学科、长期照护,并指向以队列内、双重结局纵向设计为基础的研究议程。

2胃癌/胃切除 (1篇)

基础研究 (1篇)

Science advances IF 13.9 2026-10-30 PMID: 42962000
Regulatory T cell (Treg) accumulation within the tumor microenvironment is a major contributor to immune evasion and immunotherapy resistance. However, the metabolic signals orchestrating Treg lineage commitment remain poorly defined. We identify that the oxysterol 7α,25-dihydroxycholesterol (7α,25-OHC), produced by Vimentin+ stromal cells, acts through GPR183 to promote Treg differentiation and suppressive identity. In patients with gastric cancer (GC), GPR183+ Treg infiltration correlates with advanced disease and poor survival. In syngeneic tumor models, conditional GPR183 deletion, specifically in CD4+ T cells or Treg cells, demonstrates its cell-intrinsic requirement for high-cholesterol-diet-induced Treg expansion and tumor growth, thereby abrogating immune evasion and restoring CD8+ T cell effector function. Mechanistically, 7α,25-OHC-GPR183 signaling activates the AXL-JAK2-STAT5 pathway to reinforce Foxp3 expression. Last, GPR183 antagonism modestly enhances anti-PD-1 efficacy in a model-dependent manner and prevents therapy-induced Treg expansion. These findings identify the 7α,25-OHC-GPR183-AXL axis as a potential metabolic checkpoint linking cholesterol metabolism to immune suppression, suggesting a potential therapeutic strategy to enhance antitumor immunity.
中文摘要:调节性T细胞(Treg)在肿瘤微环境中积聚是免疫逃逸和免疫治疗耐药的重要驱动因素。然而,调控Treg谱系定向的代谢信号仍不清楚。我们发现,由波形蛋白阳性(Vimentin+)基质细胞产生的氧固醇7α,25-二羟基胆固醇(7α,25-OHC)通过GPR183促进Treg分化和抑制性特征。在胃癌患者中,GPR183+ Treg浸润与晚期疾病和较差生存相关。在同系肿瘤模型中,CD4+ T细胞或Treg细胞特异性条件性敲除GPR183表明,GPR183是细胞内在的高胆固醇饮食诱导Treg扩增和肿瘤生长所必需,敲除后可消除免疫逃逸并恢复CD8+ T细胞效应功能。机制上,7α,25-OHC-GPR183信号激活AXL-JAK2-STAT5通路以强化Foxp3表达。最后,GPR183拮抗以模型依赖的方式适度增强抗PD-1疗效,并阻止治疗诱导的Treg扩增。这些发现将7α,25-OHC-GPR183-AXL轴确定为连接胆固醇代谢与免疫抑制的潜在代谢检查点,提示一种增强抗肿瘤免疫的潜在治疗策略。

3疝修补/腹壁外科 (1篇)

临床研究 (1篇)

JAMA surgery IF 15.6 2026-10-28 PMID: 42949738
Sex-based differences in ventral hernia repair (VHR) outcomes remain incompletely characterized. To compare short-term clinical outcomes, recurrence through 3 years, and patient-reported outcomes between female and male patients undergoing VHR. This cohort study included patients undergoing VHR from January 2012 through December 2023, with follow-up through 3 years. Data were from the Abdominal Core Health Quality Collaborative (ACHQC), a prospective, multi-institutional clinical registry. Participants were adults undergoing primary or incisional VHR whose data were recorded in the ACHQC database. Data analysis was performed from May to September 2026. Sex (female vs male). Primary outcomes included 30-day wound morbidity, comprising surgical site infection (SSI), surgical-site occurrence (SSO), and SSO requiring procedural intervention (SSO-PI), readmission, and length of stay. Secondary outcomes included pragmatic recurrence at 30 days, 1 year, 2 years, and 3 years and patient-reported quality of life and pain. Multivariable logistic regression assessed associations between sex and outcomes. Among 31 358 patients, 14 303 (45.6%) were female and 17 055 (54.4%) were male. Women were younger than men (mean [SD] age, 55.0 [14.6] vs 56.5 [13.0] years, respectively) and had higher body mass index (mean [SD], 32.1 [7.6] vs 31.7 [5.9], respectively). Women presented with more complex hernia phenotypes, including higher rates of incisional, recurrent, and larger hernias. Compared with men, women experienced higher 30-day readmission (483 [3.4%] for women vs 428 [2.5%] for men), SSI (370 [2.6%] vs 284 [1.7%], respectively) SSO (1323 [9.2%] and 1286 [7.5%], respectively), and SSO-PI (517 [3.6%] vs 434 [2.5%], respectively; all P < .001), with no differences in reoperation or mortality. Female sex was independently associated with higher odds of SSI (odds ratio [OR], 1.40; 95% CI, 1.17-1.67) and SSO-PI (OR, 1.21; 95% CI, 1.04-1.40) after incisional hernia repair. Clinical outcomes and recurrence were similar at 1 year; however, women had higher recurrence at 2 years (444 [19.3%] vs 406 [15.7%] men) and 3 years (351 [20.9%] vs 320 [17.6%] men). Women reported worse baseline quality of life and pain but greater improvement after 1 year. This study found that women undergoing VHR presented with greater hernia complexity and experienced higher early wound morbidity and increased late recurrence, while achieving substantial patient-reported benefit. These findings may inform sex-specific risk stratification and counseling, although further studies with more longitudinal follow-up are needed.
中文摘要:腹壁疝修补(VHR)结局的性别差异仍未充分明确。该研究比较女性与男性VHR患者的短期临床结局、3年复发及患者报告结局。这项队列研究纳入2012年1月至2023年12月接受VHR的患者,随访至3年。数据来自腹壁核心健康质量协作组(ACHQC)这一前瞻性、多机构临床登记数据库。研究对象为在ACHQC数据库中记录的原发或切口VHR成年患者。数据分析于2026年5月至9月进行。暴露为性别(女性 vs 男性)。主要结局包括30天伤口相关并发症,涵盖手术部位感染(SSI)、手术部位事件(SSO)、需操作干预的SSO(SSO-PI)、再入院和住院时间。次要结局包括30天、1年、2年和3年的实用性复发,以及患者报告的生活质量和疼痛。采用多变量logistic回归评估性别与结局的关联。31 358例患者中,女性14 303例(45.6%),男性17 055例(54.4%)。女性较男性年轻(平均[SD]年龄55.0[14.6]岁 vs 56.5[13.0]岁),体质指数更高(平均[SD]32.1[7.6] vs 31.7[5.9])。女性疝表型更复杂,切口疝、复发性疝和较大疝比例更高。与男性相比,女性30天再入院(女性483例[3.4%] vs 男性428例[2.5%])、SSI(370例[2.6%] vs 284例[1.7%])、SSO(1323例[9.2%] vs 1286例[7.5%])和SSO-PI(517例[3.6%] vs 434例[2.5%])更高,所有P<.001,再手术或死亡无差异。切口疝修补后,女性性别与SSI(比值比[OR]1.40;95%CI 1.17-1.67)和SSO-PI(OR 1.21;95%CI 1.04-1.40)更高风险独立相关。1年时临床结局和复发相似;但女性2年复发更高(444例[19.3%] vs 男性406例[15.7%]),3年复发更高(351例[20.9%] vs 男性320例[17.6%])。女性基线生活质量和疼痛更差,但1年后改善更大。该研究发现,接受VHR的女性疝更复杂,早期伤口相关并发症和晚期复发更高,同时获得明显的患者报告获益。这些结果可能有助于性别特异性风险分层和咨询,但仍需更多纵向随访研究。

4胃肠腺癌 (1篇)

基础研究 (1篇)

Cancer letters IF 11.8 2026-10-28 PMID: 42580433
Gastrointestinal (GI) adenocarcinomas pose a significant therapeutic challenge due to highly immunosuppressive tumor microenvironments that limit effective antitumor immune responses. Dense stromal fibrosis, immune exclusion and poor responses to immune checkpoint inhibitors are hallmarks of treatment-resistant malignancies, most notably pancreatic ductal adenocarcinoma (PDAC) and subsets of gastric cancer. In this regard, IL-15 superagonists such as N-803, NIZ985, RLI, and NKTR-255 have emerged as promising immunotherapeutic candidates, as they selectively expand natural killer (NK) cells and CD8+ T-cells without the systemic toxicity and regulatory T-cell activation observed with IL-2 therapy. IL-15 superagonists have emerged as more effective therapeutic agents when used in conjunction with local inhibitors of TGF-β and IL-10, stromal remodeling, and vascular normalization. They are supported by increasingly conclusive mechanistic, preclinical and early clinical data. A combination of these interventions circumvents extracellular matrix-provoked immune barriers, reverses VEGF-induced endothelial dysfunction, and enhances the trafficking of lymphocytes into tumor cores. Moreover, several localized therapeutic delivery strategies, such as endoscopic delivery, implantable depots, biomaterial scaffolds, and nanocarriers, can improve intratumoral cytokine retention and reduce systemic inflammatory toxicity. Together, these advances define a new paradigm for cytokine-immunotherapy: IL-15 superagonists serving as key mediators of reprogramming of the tumor microenvironment. Therapeutic strategies targeting IL-15 have the potential to restore cytotoxic immunity, improve access to immune cells, and promote responsiveness to the checkpoint blockade, making them a promising yet investigational approach to converting immune-cold GI malignancies into more treatment-responsive disease states, though further clinical validation is required.
中文摘要:胃肠腺癌因高度免疫抑制的肿瘤微环境限制有效的抗肿瘤免疫应答,构成显著的治疗难题。密集的间质纤维化、免疫排斥以及对免疫检查点抑制剂反应不佳,是治疗抵抗性恶性肿瘤的特征,最典型的是胰腺导管腺癌(PDAC)和部分胃癌。IL-15 超级激动剂 N-803、NIZ985、RLI 和 NKTR-255 已成为有前景的免疫治疗候选物,可选择性扩增自然杀伤(NK)细胞和 CD8+ T 细胞,且不出现 IL-2 治疗中观察到的全身毒性和调节性 T 细胞活化。与 TGF-β 和 IL-10 的局部抑制剂、间质重塑及血管正常化联合使用时,IL-15 超级激动剂表现出更强的治疗作用。越来越多的机制研究、临床前和早期临床数据支持这一点。这些干预联合可绕过细胞外基质造成的免疫屏障,逆转 VEGF 诱导的内皮功能障碍,并增强淋巴细胞进入肿瘤核心的转运。内镜递送、可植入储库、生物材料支架和纳米载体等局部治疗递送策略,能够提高瘤内细胞因子滞留并降低全身炎症毒性。这些进展共同定义了细胞因子免疫治疗的新范式:IL-15 超级激动剂作为重编程肿瘤微环境的关键介质。靶向 IL-15 的治疗策略有望恢复细胞毒性免疫、改善免疫细胞的可及性并促进对检查点阻断的应答,是将免疫冷型胃肠恶性肿瘤转化为对治疗更敏感疾病状态的有前景但仍处于研究阶段的方法,尚需进一步临床验证。